阿斯利康將攜肝癌、乳腺癌和膀胱癌III期臨床研究數據及罕見病潛在同類首創療法，亮相2026美國臨床腫瘤學會（ASCO）年會

阿斯利康

2026-05-23 16:17 1621

EMERALD-3研究的重磅報告將展示英飛凡聯合英卓凡用于早期肝癌治療的獲益

來自SERENA-6、DESTINY-Breast09和TROPION-Breast02的III期臨床研究數據覆蓋轉移性乳腺癌的三種主要亞型

CARES研究三期結果顯示抗淀粉樣原纖維單克隆抗體anselamimab對于κappa型AL輕鏈淀粉樣變性患者臨床獲益顯著

上海2026年5月23日 /美通社/ -- 在2026年5月29日-6月2日召開的美國臨床腫瘤學會（ASCO）年會上，阿斯利康將憑借多樣化且行業領先的產品組合和研發管線，公布多項最新研究數據，進一步踐行讓癌癥不再成為致死主因和改善罕見病患者治療結局的宏偉愿景。

會上將公布超過85個摘要，其中涵蓋10款已獲批藥物和13款潛在新藥、25項口頭報告。亮點包括：

EMERALD-3：評估了度伐利尤單抗與曲麥利尤單抗，聯合或不聯合侖伐替尼和經動脈化療栓塞術（TACE），用于治療適于栓塞的不可切除肝細胞癌（HCC）患者的III期臨床研究（口頭摘要#LBA4000）。
CARES：來自瑞頌制藥（阿斯利康罕見病業務）潛在的首創抗淀粉樣原纖維單克隆抗體anselamimab 的 III 期臨床研究：用于治療新診斷輕鏈型淀粉樣變性患者，并將公布kappa或lambda輕鏈型淀粉樣變患者的亞組分析結果（口頭摘要#7501）。
SERENA-6：評估了Camizestrant 聯合廣泛獲批的細胞周期蛋白依賴性激酶（CDK）4/6抑制劑，用于一線治療激素受體（HR）陽性、人表皮生長因子受體2（HER2）陰性且腫瘤出現ESR1突變的晚期乳腺癌患者的三期試驗——第二次無進展生存期（PFS2）最終結果，循環腫瘤 DNA（ctDNA）清除數據及其與長期療效結局的相關性分析（口頭摘要 #LBA1007）。
BLUESTAR：評估了在I/IIa期BLUESTAR臨床試驗中，靶向B7-H4的新型抗體偶聯藥物（ADC）Puxitatug samrotecan（Puxi-Sam）用于治療已接受標準治療的復發性或轉移性B7-H4陽性子宮內膜癌和卵巢癌患者的安全性和有效性更新結果。（快速口頭摘要#5515）。Puxi-Sam近日已被美國食品藥品監督管理局（FDA）授予"突破性療法"認定。
PRIMAVERA：評估了蛋白質精氨酸甲基轉移酶5(PRMT5)抑制劑AZD3470單藥用于治療復發/難治性經典型霍奇金淋巴瘤的首次人體試驗PRIMAVERA I期臨床研究的安全性和初步療效（口頭摘要 #7003）。
NT-175 I期初步結果：針對TP53 R175H突變的不可切除、晚期及/或轉移性胰腺腺癌等實體腫瘤的T細胞受體療法（口頭摘要#2506）。
TROPION-Breast02：評估了TROPION-Breast02 III期臨床試驗中，德達博妥單抗用于無法接受PD-1/PD-L1抑制劑治療的局部復發不可手術或轉移性三陰性乳腺癌（TNBC）患者一線治療的額外療效終點（口頭摘要 #1002）。
DESTINY-Breast09：評估了在DESTINY-Breast09 III期臨床試驗中，德曲妥珠單抗聯合帕妥珠單抗用于HER2陽性轉移性乳腺癌患者的一線治療，基于完全緩解、部分緩解或疾病穩定/進展對治療持續時間和臨床結局進行的探索性分析（快速口頭摘要#1021）。
POTOMAC：評估了在III期POTOMAC臨床試驗中，度伐利尤單抗聯合卡介苗（BCG）誘導和維持治療高危非肌層浸潤性膀胱癌患者的五年總生存期與患者報告結果（快速口頭摘要#4624）。

阿斯利康全球執行副總裁、腫瘤研發負責人高書璨（Susan Galbraith）表示："本次ASCO大會上公布的創新藥物和下一代療法數據，進一步推動了我們的戰略——通過新型聯合療法應用于疾病早期階段，并不斷拓展創新療法來改變腫瘤患者治療結局。德曲妥珠單抗、德達博妥單抗和camizestrant的重磅數據證實了它們在乳腺癌領域變革性的潛力。我們也很高興分享T細胞受體療法NT-175和PRMT5抑制劑AZD3470的首次臨床數據，以及公司自主研發的最領先的抗體偶聯藥物之一Puxi-Sam的最新數據，Puxi-Sam近日已被美國食品藥品監督管理局（FDA）授予'突破性療法'認定。這些數據充分彰顯了腫瘤研發管線的強大實力與深厚底蘊。"

阿斯利康全球執行副總裁，腫瘤業務負責人Dave Fredrickson表示："EMERALD-3的研究數據證明，度伐利尤單抗聯合曲麥利尤單抗用于早期肝癌的治療，是我們將免疫療法遷入癌癥早期階段治療策略的成功例證，進而改善患者治療結局。僅是在過去六個月中，我們的五款腫瘤藥物獲批了超過十個不同的適應癥，日益豐富的產品組合正在惠及更多患者，這充分彰顯了阿斯利康在腫瘤領域的創新質量與業務實力。"

瑞頌制藥臨床開發、注冊及患者安全負責人Gianluca Pirozzi表示："CARES III期臨床研究結果突顯了anselimamab作為首創抗淀粉樣原纖維單克隆抗體，在治療kppa輕鏈型淀粉樣變性患者中的潛力。其創新機制旨在靶向清除受累器官中的淀粉樣蛋白沉積，有望延長患者生存期并減少因心血管事件引發的住院頻次。"

阿斯利康與第一三共聯合開發和商業化德曲妥珠單抗和德達博妥單抗。

阿斯利康在2026 ASCO年會公布的重磅數據^[^1]

主要作者 Lead Author	摘要標題 Abstract Title	詳情Presentation details (CDT)
抗體偶聯藥物 Antibody drug conjugates
Loi, S	Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY- Breast07.	Abstract #1012 Clinical Science Symposium 31 May 2026 09:18
Cescon, DW	First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple- negative breast cancer (TNBC) for who immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.	Abstract #1002 Oral Abstract Session 2 June 2026 10:09
Mileshkin, LR	Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study.	Abstract #5515 Rapid Oral Abstract Session 30 May 2026 09:00
Park, YH	A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P).	Abstract #1021 Rapid Oral Abstract Session 31 May 2026 12:42
Untch, M	Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP).	Abstract #516 Rapid Oral Abstract Session 1 June 2026 10:57
Shitara, K	Sonesitatug vedotin (Sone-Ve) monotherapy in patients (pts) with claudin 18.2–positive (CLDN18.2+) advanced or metastatic gastric or gastroesophageal junction (GEJ) cancers: Data from CLARITY- PanTumor01.	Abstract #4023 Poster Session 30 May 2026 09:00
Janjigian, Y	First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.	Abstract #4022 Poster Session 30 May 2026 09:00
Zhang, Y	Trastuzumab deruxtecan (T-DXd) for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY- PanTumor03 Part 1 primary analysis.	Abstract #3026 Poster Session 30 May 2026 13:30
免疫腫瘤學 Immuno-oncology
Abou-Alfa, GK	Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).	Abstract #LBA4000 Oral Abstract Session 1 June 2026 09:45
Skoulidis, F	Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.	Abstract #8515 Rapid Oral Abstract Session 30 May 2026 13:45
Heymach, JV	Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.	Abstract #8015 Rapid Oral Abstract Session 31 May 2026 17:30
De Santis, M	Durvalumab (D) in combination with BCG induction and maintenance (I + M) therapy for BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC.	Abstract #4624 Rapid Oral Abstract Session 1 June 2026 08:12
免疫腫瘤學與雙特異性抗體 IO Bispecifics
O'Sullivan, CC	Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial.	Abstract #LBA514 Rapid Oral Abstract Session 1 June 2026 10:45
Zhou, J	First-line rilvegostomig (R) + chemotherapy (CTx) in advanced biliary tract cancer (BTC): Updated analysis of GEMINI-Hepatobiliary substudy 2 cohort A.	Abstract #88 Poster Session 30 May 2026 09:00
Guo, Y	Volrustomig monotherapy for recurrent/metastatic HNSCC: Substudy 2 of the eVOLVE-02 phase 2 study.	Abstract #482 Poster Session 30 May 2026 13:30
腫瘤驅動因素和耐藥性 Tumour drivers and resistance
Wang, Z	Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study).	Abstract #LBA101 Clinical Science Symposium 30 May 2026 08:40
Bidard, FC	First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial.	Abstract #LBA1007 Oral Abstract Session 2 June 2026 11:57
Peng, Z	A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinomas.	Abstract #4011 Rapid Oral Abstract Session 1 June 2026 13:27
細胞療法 Cell Therapy
Surana, R	Initial phase 1 study results of NT-175 engineered T-cell therapy in TP53 R175H–mutated unresectable advanced solid tumors.	Abstract #2506 Oral Abstract Session 31 May 2026 10:00
表觀遺傳學 Epigenetics
Derenzini, E	A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA).	Abstract #7003 Oral Abstract Session 30 May 2026 16:00
罕見病 Rare Disease
Wechalekar, AD	Phase 3 randomized trial to evaluate the impact of anselamimab on all- cause mortality in κ light chain amyloidosis.	Abstract #7501 Oral Abstract Session 29 May 2026 14:57
Chen, AP	Final analysis of KOMET (NCT04924608), a phase 3 study of selumetinib in adults with NF1-PN.	Abstract #3110 Poster Session 30 May 2026 13:30